Patient was followed up over the course of 30 years. In 1978, after severe systemic infection followed by fever, pulmonary edema, and numerous neurological manifestations, patient was differentially diagnosed with apoplectic form of multiple sclerosis (MS), which was confirmed a year later via neurological and MRI findings. Approximately 20 years following the initial attack, sarcoidosis was diagnosed during the regular preoperative procedures required for cataract surgery. As consequence of lower immune system, infectious granulomatosis in form of pulmonary tuberculosis developed. Ophthalmological findings revealed bilateral retrobulbar neuritis (RBN) approximately six years after initial attack. This developed into total uveitis with retinal periphlebitis and anterior granulomatous uveitis—all of which are clinically similar in both MS and sarcoidosis. 1. Introduction Sarcoidosis and multiple sclerosis (MS) belong to a group of systemic vasculitides. Besides trauma, MS as chronic inflammation with demyelination and scarring is the most frequent cause of neurologic disability. It occurs more commonly in young middle aged females. MS, disease disseminated in time and space, is characterized by frequent recidivism. If full recovery has not been achieved, definitive neurological deficits persist. During the course of the disease, magnetic resonance imaging (MRI) reveals presence of demyelinating plaques, while liquor analysis shows oligoclonal response [1–4]. Lesions that occur in MS are characterized by perivenous cuffing and tissue infiltration by mononuclear cells (predominantly T lymphocytes and macrophages). Demyelination appears as disease progresses and as macrophages and microglial cells form the myelin debris. Due to proliferation of astrocytes, scarring occurs. Damage of myelin sheet can in most cases be connected to previous viral infection. It is believed that stress is also one of the important triggering factors [5–8]. Initial symptoms of the disease are muscle weakness in one or more limbs, blurred vision (secondary to optic neuritis), sensory disturbances, ataxia, diplopia, and so forth. However, no clinical signs or findings from diagnostic procedures are unique to MS [9, 10]. Ocular manifestations such as retrobulbar neuritis (RBN), retinal vasculitis (RV), and anterior granulomatous uveitis occur as part of MS. According to some authors, RV (periphlebitis) is a primary inflammation subsequent to vitreal inflammation and snow bank formation [3, 11]. Sarcoidosis is a multisystemic, granulomatous disease of unknown etiology. As of yet, no
References
[1]
C. H. Polman, S. C. Reingold, B. Banwell et al., “Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria,” Annals of Neurology, vol. 69, no. 2, pp. 292–302, 2011.
[2]
J. Graves and L. J. Balcer, “Eye disorders in patients with multiple sclerosis: natural history and management,” Clinical Ophthalmology, vol. 4, no. 1, pp. 1409–1422, 2010.
[3]
L. Chen and L. K. Gordon, “Ocular manifestations of multiple sclerosis,” Current Opinion in Ophthalmology, vol. 16, no. 5, pp. 315–320, 2005.
[4]
A. Stanojevic-Paovic, “Chapter II,” in Uveitis, A. Stanojevic-Paovic, Ed., pp. 105–144, School of Medicine, University of Belgrade, Belgrade, Serbia, 2008.
[5]
A. Langer-Gould, K. B. Albers, S. K. van den Eeden, and L. M. Nelson, “Autoimmune diseases prior to the diagnosis of multiple sclerosis: a population-based case-control study,” Multiple Sclerosis, vol. 16, no. 7, pp. 855–861, 2010.
[6]
J. P. Campbell, H. A. Leder, Y. J. Sepah, et al., “Wide-field retinal imaging in the management of noninfectious posterior Uveitis,” American Journal of Ophthalmology, vol. 154, no. 5, pp. 908–911, 2012.
[7]
K. Turaka and J. S. Bryan, “Does fingolimod in multiple sclerosis patients cause macular edema?” Journal of Neurology, vol. 259, no. 2, pp. 386–388, 2012.
[8]
N. Jain and M. T. Bhatti, “Fingolimod-associated macular edema: incidence, detection, and management,” Neurology, vol. 78, no. 9, pp. 672–680, 2012.
[9]
K. M. Galetta, J. Graves, L. S. Talman, et al., “Visual pathway axonal loss in benign multiple sclerosis: a longitudinal study,” Journal of Neuro-Ophthalmology, vol. 32, no. 2, pp. 116–123, 2012.
[10]
L. S. Talman, E. R. Bisker, D. J. Sackel et al., “Longitudinal study of vision and retinal nerve fiber layer thickness in multiple sclerosis,” Annals of Neurology, vol. 67, no. 6, pp. 749–760, 2010.
[11]
J. M. Gelfand, R. Nolan, D. M. Schwartz, J. Graves, and A. J. Green, “Microcystic macular oedema in multiple sclerosis is associated with disease severity,” Brain, vol. 135, part 6, pp. 1786–1793, 2012.
[12]
A. D. Birnbaum, F. S. Oh, A. Chakrabarti, H. H. Tessler, and D. A. Goldstein, “Clinical features and diagnostic evaluation of biopsy-proven ocular sarcoidosis,” Archives of Ophthalmology, vol. 129, no. 4, pp. 409–413, 2011.
[13]
C. P. Herbort, N. A. Rao, M. Mochizuki, et al., “International criteria for the diagnosis of ocular sarcoidosis: results of the first international workshop on ocular sarcoidosis (IWOS),” Ocular Immunology and Inflammation, vol. 17, no. 3, pp. 160–169, 2009.
[14]
G. W. Hunninghake, U. Costabel, M. Ando, et al., “ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society World Association of Sarcoidosis and other Granulomatous Disorders,” Sarcoidosis, Vasculitis and Diffuse Lung Diseases, vol. 16, no. 2, pp. 149–173, 1999.
[15]
R. P. Baughman, A. S. Teirstein, M. A. Judson et al., “Clinical characteristics of patients in a case control study of sarcoidosis,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 10 I, pp. 1885–1889, 2001.
[16]
K. Babu, R. Kini, R. Mehta, M. P. Abraham, D. Subbakrishna, and K. R. Murthy, “Clinical profile of ocular sarcoidosis in a South Indian patient population,” Ocular Immunology and Inflammation, vol. 18, no. 5, pp. 362–369, 2010.
[17]
M. Evans, O. Sharma, L. LaBree, R. E. Smith, and N. A. Rao, “Differences in clinical findings between Caucasians and African Americans with biopsy-proven sarcoidosis,” Ophthalmology, vol. 114, no. 2, pp. 325–333, 2007.
[18]
S. R. Boyd, S. Young, and S. Lightman, “Immunopathology of the noninfectious posterior and intermediate Uveitides,” Survey of Ophthalmology, vol. 46, no. 3, pp. 209–233, 2001.
[19]
E. E. Lower, J. P. Broderick, T. G. Brott, and R. P. Baughman, “Diagnosis and management of neurological sarcoidosis,” Archives of Internal Medicine, vol. 157, no. 16, pp. 1864–1868, 1997.
[20]
B. M. Burkholder and J. P. Dunn, “Multiple Sclerosis-associated Uveitis,” Expert Review of Ophthalmology, vol. 7, no. 6, pp. 587–594, 2012.
